Stanley Black & Decker (SWK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 7 | $107.29 | $111.3 | $4.01 | 3.74% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 336 | $4,580.13 | $5,342.4 | $762.27 | 16.64% |
Ana-Maria Ignat Covestor Ltd | 32 | $465.6 | $508.8 | $43.2 | 9.28% |
Alexandra Stickelman Root Financial Partners, LLC | 1 | $17 | $15.9 | -$1.1 | -6.47% |
Mark Schafer Police & Firemen's Retirement System of New Jersey | 1,369 | $20,179 | $21,767.1 | $1,588.1 | 7.87% |
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MD Michael Diana Maxim Group | - | - | - | - | - |
| Capital Markets Industry | Financials Sector | Jody. D Staggs CEO | NASDAQ (NMS) Exchange | 78501P203 CUSIP |
| US Country | 24 Employees | - Last Dividend | 24 Apr 2025 Last Split | 22 Sep 1999 IPO Date |
SWK Holdings Corporation, headquartered in Dallas, Texas, is a specialized financial service and asset management firm operating predominantly within the United States. Initially known as Kana Software, Inc., the company underwent a name change to SWK Holdings Corporation in December 2009. Since its inception in 1996, SWK Holdings has distinguished itself by focusing on the life sciences sector, providing a unique blend of financial solutions and services to a diversified client base. The company functions through two main divisions: Finance Receivables and Pharmaceutical Development, catering to a wide array of needs in the life science community, including biotechnology, medical devices, diagnostics, animal health, and pharmaceuticals.
This segment of SWK Holdings offers tailored financing solutions targeting a broad spectrum of life science companies and inventors. The clientele encompasses entities from the biotechnology, medical device, diagnostics, animal health, and pharmaceutical industries, among others. By providing flexible financing options, SWK Holdings supports the growth and advancement of companies and technologies within these sectors. Additionally, this segment extends non-discretionary investment advisory services to institutional clients, managing accounts specifically geared towards investments in life science finance.
SWK Holdings' Pharmaceutical Development segment delivers wide-ranging services in pharmaceutical development, formulation, and manufacturing. It is notably recognized for the Peptelligence platform, a proprietary oral drug delivery technology that offers innovative formulation solutions. The segment’s capabilities facilitate the development process for clients, from conceptualization to final product creation, encompassing both development services and formulation technologies. Furthermore, SWK Holdings engages in the intellectual property licensing business, leveraging its developments and technologies to establish partnerships and collaborations within the industry.